Edition 1 / March 2021
Welcome to the first 2021 edition of Corden Connect! I would like to begin by saying THANK YOU to both existing and new customers for the ongoing trust & loyalty you placed in us throughout these unforeseen circumstances over the past year – your collaboration was invaluable to our organization.
During a year dominated by the COVID-19 pandemic, CordenPharma realized a remarkably strong operational & financial performance, in which we demonstrated unprecedented resilience and flexibility in supplying customers with their existing and new medications from our global network of facilities.
As seen in our 2020 Highlights presentation below, CordenPharma contributed to the development and supply of more than 100 clinical projects in various phases, as well as the approval and subsequent launch of five new innovative medications to support customers, and ultimately their patients, in addressing unmet medical needs. In addition, we increased our ongoing support to supply critical Lipids for breakthrough mRNA vaccines from CordenPharma Colorado, Chenôve, and Switzerland, and the life-saving Drug Product Propofol from CordenPharma Caponago.
In this context, my sincere gratitude goes to all employees for their relentless efforts and demonstrated ability to work together over the last year. I am very proud to work with such a dedicated team. Now more than ever, the direct impact you have on patients inspires us every day to strive for excellence in delivering high quality products on time with integrity, transparency & flexibility. This is our promise, and the yardstick by which we measure our progress and efforts of continuous improvement.
As 2021 marks the 15 Year Anniversary for CordenPharma, I am pleased to announce we are off to a solid start in the new decade, and we will continue to focus our growth on four key Technology Platforms: Highly Potent & Oncology, Peptides, Lipids & Carbohydrates, Small Molecules, and Injectables. In addition, we will strengthen our Fully Integrated Supply Solutions (API Starting Materials > Intermediates > APIs > Drug Products > Packaging) to bring you the maximum benefit for this increased demand.
Finally, we hope to meet with you in person at any of the planned trade shows in the second half of the year – the CordenPharma team would be delighted to discuss your ongoing & future project needs. In the meantime, we will continue to rely on virtual tools to ensure connectivity with customers, including virtual site tours and audits. Although these tools will never replace the energy that comes from meeting face-to-face with customers, the advantages of reduced travel time and a smaller carbon footprint have created a surprisingly positive impact in the meantime.
As always, feel free to reach out to your Key Account Managers to schedule a meeting or provide any feedback on how we can better serve you in the future! We look forward to a successful 2021 and new decade ahead!
Dr. Michael Quirmbach
President & CEO, CordenPharma
Stay up to date with the latest thought leadership articles and news from CordenPharma.